Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TheraclionFRA:941 -2.34%19 Gross Margin % is -500.28% as of Dec. 2025. GuruFocus rates FRA:941 with a GF Score™ of 19/100 and a GF Value™ of €0.24 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Theraclion ranks worse than 98.76% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Theraclion's Gross Profit for the
six
months ended in Dec. 2025 was €-1.76 Mil. Theraclion's Revenue for the
six
months ended in Dec. 2025 was €0.35 Mil. Therefore, Theraclion's Gross Margin % for the quarter that ended in Dec. 2025 was -500.28%.
Warning Sign:
Theraclion gross margin has been in long-term decline. The average rate of decline per year is -5.5%.
The historical rank and industry rank for Theraclion's Gross Margin % or its related term are showing as below:
FRA:941'
s Gross Margin % Range Over the Past 10 Years
Min: -345.9 Med: -152.86 Max: -42.47
Current: -240.81
During the past 13 years, the highestGross Margin % of Theraclion was -42.47%. The lowest was -345.90%. And the median was -152.86%.
FRA:941's Gross Margin % is ranked worse than 98.76% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 52.07
vs FRA:941: -240.81
Theraclion had a gross margin of -500.28% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Theraclion was -5.50% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Theraclion had a gross margin of -500.28% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Theraclion Gross Margin % Related Terms
Theraclion Gross Margin % Historical Data
* Premium members only.
The historical data trend for Theraclion's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:941 vs ABT, SYK, MDT: Gross Margin % Comparison
For the Medical Devices subindustry, Theraclion's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theraclion Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Theraclion's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Theraclion's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Theraclion (FRA:941) has a Gross Margin % of -500.28% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Theraclion and its competitors. According to the industry distribution chart, Theraclion ranks #795 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 98.8%.
Is Theraclion's Gross Margin % too high?
Theraclion's current Gross Margin % is -500.28%. Based on the distribution chart, Theraclion ranks #795 out of 805 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Theraclion has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theraclion's Gross Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Theraclion ranks #795 out of 805 companies for Gross Margin %. This places Theraclion in the lower half of its industry. The industry median Gross Margin % is 52.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.07, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Theraclion and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theraclion's current Gross Margin % is -500.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theraclion stock overvalued right now?
Based on GuruFocus' analysis, Theraclion (FRA:941) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.24, compared to a current price of €0.54 — trading 125.8% above its estimated fair value. The current Gross Margin % is -500.28%. Theraclion's overall GF Score™ is 19/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Theraclion (FRA:941), the current Gross Margin % is -500.28% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theraclion (FRA:941) Overvalued in 2026?
Based on GuruFocus' analysis, Theraclion stock appears to be overvalued.
The current stock price of €0.54 is trading 125.8% above its estimated GF Value™ of €0.24.
GuruFocus considers Theraclion to be Significantly Overvalued.
Key valuation signals for FRA:941:
Gross Margin %: -500.28%
GF Value™: €0.24 vs. price of €0.54 (125.8% above fair value)
No single metric tells the full story. See the FRA:941 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theraclion specializes in developing, manufacturing, and marketing echotherapy equipment, associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules. Its products include Sonovein, Echopulse, and Epack.
19GF Score
Get the complete analysis for FRA:941
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:941 has been successfully added to your 
